DOCSLIB.ORG

Partnering Data As of November 2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Partnering Data As of November 2018 a BioJapan / Regenerative Medicine Japan 2018 Partnering Data As of November 2018 2019年10月9日(水)〜11日(⾦) Oct. 9WED ー11パシフィコ横浜FRI ――――――――――――――――――October 9–11, 2019 Pacifico Yokohama,Pacifico Japan Yokohama 2019 Japan: the World’s Second Largest Pharmaceutical Market Representing 8% of the world pharmaceutical market in 2016, Japan’s pharma sector remains one of the largest in the world. While Japan is often said to be overly insular, a recent sharp rise in the number of international forays from larger Japanese pharmaceutical companies—including many significant M&A deals and the establishment of new R&D sites around the world—indicates a bright and increasingly international future for the industry. Furthermore, the nation’s ageing population is creating an ever-larger domestic market for medicinal products and services, and in particular the easing of regulatory restrictions is set to turn Japan into a hotbed for regenerative medicine-related R&D. 1200 Japan 1000 Asia-Pacific (Excl. Japan), 800 Africa, Middle East 600 Europe 400 Central / S. America 200 0 N. America 2012 2013 2014 2015 2016 Source:JPMA Databook Domestic Japanese Sales Rankings (Distributor Level, FY2017) Company Sales: USD Company Sales: USD (November 2018 rates) (November 2018 rates) 1 Takeda 6,317,258,929 11 Eli Lilly Japan 2,496,991,071 2 Daiichi Sankyo 5,971,785,714 12 Ono 2,266,526,786 3 Astellas 4,919,303,571 13 Bayer 2,146,785,714 4 Pfizer 4,291,142,857 14 Kyowa Hakko Kirin 2,076,625,000 5 Chugai 4,286,526,786 15 Eizai 1,865,482,143 6 Mitsubishi Tanabe 3,230,785,714 16 Sumitomo Dainippon 1,575,205,357 7 MSD 3,203,116,071 17 AstraZeneca 1,556,473,214 8 Otsuka Holdings 3,036,017,857 18 Nichi-iko 1,490,696,429 9 Novartis 2,702,383,929 19 Santen 1,470,553,571 10 GSK 2,638,955,357 20 Sawai 1,451,696,429 Copyright 2018 JTB Communication Design, Inc. 2 Financial Results of the Leading Japanese Pharmaceutical Manufacturers (Japan FY2016 Consolidated Accounts) Sales: USD Company (November 2018 rates) Takeda 15,464,741,071 Astellas 11,711,205,357 Otsuka Holdings 10,674,526,786 Daiichi Sankyo 8,527,892,857 Eisai 4,813,366,071 Mitsubishi Tanabe 3,785,508,929 Dainippon Sumitomo 3,675,339,286 Kyowa Hakko Kirin 3,062,669,643 Shionogi 3,025,803,571 Taisho 2,497,973,214 Ono 2,185,687,500 Santen 1,777,642,857 Hisamitsu 1,302,901,786 Kyorin Holdings 1,030,116,071 Tsumura 1,026,375,000 Kaken 906,062,500 Nippon Shinyaku 881,973,214 Mochida 869,187,500 Kissei 640,232,143 Zaria 579,017,857 Copyright 2018 JTB Communication Design, Inc. 3 Japanese Outbound M&A Deals Japanese pharmaceutical companies are Besides this, many larger companies have becoming more global and strengthening recently been establishing and expanding their pipelines through M&A. To name just R&D sites in countries around the world. one of many, Takeda Pharmaceuticals, Notable examples include Chugai, who are the market leader in Japan, is reported to set to invest almost 500m USD into their have earmarked as much as $20 billion to Singapore research institute over the spend on overseas acquisitions of coming years, and Eisai, who established companies developing cancer, GI, and their first European research site in the CNS drugs in particular. UK in 2009. Company Takeover Candidate Deal Value (USD) Date Takeda Shire (UK) 6trillion 800billion TBD Mitsubishi Tanabe NeuroDerm (Israel) 111.7 billion Jul. 2017 Sawai Upsher-Smith Laboratories (US) 105 billion Apr. 2017 Pharmaceutical Hitachi Chemical PCT, LLC, a Caladrius (US) 75 million Mar. 2017 Takara Bio WaferGen (US) 50 million 2017 ROHTO Ophthalmos (Brazil) Undisclosed Oct. 2016 Duoc Hau Giang Pharmaceutical Taisho Undisclosed Jul. 2016 (Vietnam) Nichi-Iko Sagent Pharmaceuticals (US) 640 million Jul. 2016 Eisai Liaoning TianYi (China) 78 million Nov. 2015 ReproCELL Biopta (UK) 8 million Nov. 2015 Astellas Ocata Therapeutics (US) 379 million Nov. 2015 Sosei Group Heptares Therapeutics (UK) 400 million Feb. 2015 Denki Kagaku Kogyo Icon Genetics (Germany) 75 million Aug. 2015 Panasonic Healthcare Bayer Diabetes Care (Germany) 1.1 billion Jun. 2015 Cellular Dynamics International Fujifilm 307 million Mar. 2015 (US) JSR Corporation KBI Biopharma (US) Undisclosed Feb. 2015 Takeda Neutec (Turkey) *portfolio 121 million Feb. 2015 Sources: NIKKEI Online, Financial Times Copyright 2018 JTB Communication Design, Inc. 4 Japanese Drug Discovery Alliances Drug discovery alliances between Japanese and non-Japanese organizations are also on the rise. With over half of new medicines now stemming from biotech companies and startups, Japanese pharmaceutical companies understand the potential in developing these new drugs and bringing them to market. Company Alliance Partner Date Healios Athersys (US) Jan. 2016 Takeda Teva Pharmaceutical Industries (ISR) Nov. 2015 Astellas Chromocell (US) Sep. 2015 Mitsubishi Tanabe Pharma MedImmune (UK) Sep. 2015 Daiichi Sankyo Translational Sciences (US) Sep. 2015 Sysmex Merck (US) Jun. 2014 Eizai Biogen Idec (UK) Mar. 2014 Ono Pharmaceutical Bristol-Myers Squibb (US) Mar. 2014 Sources: NIKKEI Online Copyright 2018 JTB Communication Design, Inc. 5 Regulatory Changes Make for Faster Access to Market for Regenerative Medicine Regulatory Changes Two acts were enacted in Japan in November 2014 that made revolutionary changes to the regulatory system for regenerative medicines: the Pharmaceuticals and Medical Devices Act and the Act on the Safety of Regenerative Medicine. Pharmaceuticals and Medical Devices Act Under the Pharmaceuticals and Medical Devices Act, a new category for medicinal products called “Regenerative Medical Products” was defined, in addition to the categories of “pharmaceuticals” and “medical devices.” This allows regenerative medical products to be evaluated based on their own unique characteristics. Additionally, a new approval system for regenerative medicine products, diagrammed above, was also introduced as part of this Act. This new system has cut the time required to commercialize regenerative treatment products down to as little as two to three years, making Japan’s approval system the fastest in the world. Copyright 2018 JTB Communication Design, Inc. 6 Japan creates fastest approval system for regenerative medicines in the world Act on the Safety of Regenerative Medicine It is now possible to contract the manufacturing and processing of cells to external enterprises. The culture and processing of cells and tissues for regenerative medicine using human cells could only be conducted by medical institutions under the supervision of the physicians sponsoring the clinical research. Regenerative Medicine Japan It is with the developments that are set to take place thanks to these new regulatory changes in mind that Regenerative Medicine Japan was first held in October 2016. Organized in collaboration between the Forum for Innovative Regenerative Medicine (FIRM), the Japan Bioindustry Association (JBA), and JTB Communication Design, the new exhibition is co-located with BioJapan, sharing both an exhibition space and partnering system to maximize cross-field collaboration and encourage open innovation. Copyright 2018 JTB Communication Design, Inc. 7 BioJapan / Regenerative Medicine Japan 2018 Highlights 1200 1108 983 1000 886 879 782 800 714 678 665 607 551 600 510 538 479 403 327 400 295 200 0 2011 2012 2013 2014 2015 2016 2017 2018 Exhibitor Partnering Member Partnering Companies Participants Countries Meetings Held 1,108 1,848 10,075 2018 34 (113%↗) (110%↗) (117%↗) 2017 983 1,666 33 8,591 Exhibitors Companies Booths Countries Visitors 879 683 16,309 2018 28 (112%↗) (103%↗) (103%↗) of which 114 RMJ of which 107 RMJ 2017 782 658 26 15,711 Copyright 2018 JTB Communication Design, Inc. 8 Top Visitor Count Ranked by Industry Pharma CRO/CMO Chemical/Fiber 1 Daiichi Sankyo 1 Fujifilm Wako Pure Chemical 1 Fujifilm 2 Mitsubishi Tanabe Pharma 2 Sekisui Medical 2 Kanto Kagaku 3 Chugai Pharmaceutical Nikon Cell Innovation 3 Hitachi Kasei 4 Astellas Pharma 3 AGC 4 5 Takeda Pharmaceutical Kaneka 5 Kishi Kasei 6 ROHTO Pharmaceutical 5 Nissan Chemical 6 Meiji Seika Phrma 6 Axcelead Drug Discovery Partners 6 TORAY 8 Teijin Pharma Kyokuto Pharmaceutical Indsutrial 7 Mitsubishi Chemical 8 Otsuka Pharmaceutical 7 Oriental Yeast 8 Asahi Kasei Sumitomo Dainippon EPS 10 9 TOSOH Pharma 10 Medinet 1 Mitsui Chemical Eisai Sumika Chemical 0 JSR 11 Kowa 11 CMIC Novartis 1 NOF IQVIA Services Japan 14 Kyowa Hakko Kirin 2 Teijin Kyowa Hakko Bio Nissui Pharmaceutical 1 Sumitomo Chemical 14 Yokohama Bio Research and Supply 15 Taisho Pharmaceutical 4 Nacalai Tesque Shionogi Kishida Chemical Asahi Kasei Pharma Santen Pharmaceutical 18 Daiichi Sankyo RD Novare Machinery/ Manufacturing Taiho Pharmaceutical University/Research Institute 1 Hitachi ASKA Pharmaceutical 22 2 PHC Japan Agency for Medical Research Kyorin Pharmaceutical 1 3 Yokogawa Electric and Development (AMED) Otsuka Pharmaceutical Factory 4 Panasonic 2 The University of Tokyo JCR Pharma 5 Nikon National Institute of Advanced 3 24 Seikagaku 6 Ricoh Industrial Science and Technology Torii Pharmaceutical 7 Toppan Printing 4 Keio University Nobel Pharma 8 Shimadzu 5 Yokohama National University Kaken Pharmaceutical 9 Olympus 6 Waseda University Kissei Pharmaceutical 10 Ushio 7 Toyo University 25 Sanwa Kagaku Kenkyusho 11 Hitach High-Technologies 8 RIKEN Zeria Pharmaceutical 9 Tokyo Institute of Technology 12 SCREEN Holdings Pfizer Teikyo University 13 Canon Osaka University 10 National Center for Global Health 14 Dai Nippon Printing and Medicine 15 Hitachi Appliances Tohoku University Biotech/Drug Discovery Tokyo Medical and Dental University Central Institute of Experimental 1 Cellseed 13 Animals 2 Reprocell Kyoto University Life Science Institute Okayama University 3 Healios Yokohama City University Scohia Pharma 19 Nagoya University Chitose Laboratory Kyushu University 6 20 Kohjin Bio Academia Sinica (Taiwan) Meiji University Regenerative Medicine iPS Gateway 22 Tokyo Univesity of Science 8 Center Tsukuba University Gene Techno Science Tohkai University Reborna Biosciences 25 Hiroshima University 10 Bonac Tech Manage Integriculture Copyright 2018 JTB Communication Design, Inc.
Load more

Recommended publications
  • Nilotinib in Patients with Chronic Myeloid Leukemia: STAT2 Trial in Japan
    Haematologica HAEMATOL/2018/194894 Version 3 Haematologica HAEMATOL/2018/194894 Version 3 Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan Naoto Takahashi, Kaichi Nishiwaki, Chiaki Nakaseko, Nobuyuki Aotsuka, Koji Sano, Chikako Ohwada, Jun Kuroki, Hideo Kimura, Michihide Tokuhira, Kinuko Mitani, Kazuhisa Fujikawa, Osamu Iwase, Kohshi Ohishi, Fumihiko Kimura, Tetsuya Fukuda, Sakae Tanosaki, Saori Takahashi, Yoshihiro Kameoka, Hiroyoshi Nishikawa, and Hisashi Wakita Disclosures: 1. This study was supported by research funding from Novartis Pharmaceuticals to N.T. 2. N.T reports grants from Novartis Pharmaceuticals, during the conduct of the study; grants and personal fees from Novartis Pharmaceuticals, grants and personal fees from Otsuka, grants and personal fees from Pfizer, personal fees from Bristol-Myers Squibb, outside the submitted work; K.N reports grants from Zenyaku Kogyo Company, Limited, grants from Chugai Pharmaceutical, grants from Novartis Pharma K.K., grants from Kyowa Hakko Kirin Co, Ltd, grants from Nippon Shinyaku Co, Ltd, outside the submitted work; C.N reports personal fees from Novartis, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Pfizer, grants and personal fees from Takeda pharmaceuticals, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from Otsuka Pharmaceutical, grants and personal fees from Ono Pharmaceutical, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Asahi Kasei Pharma, grants and personal fees from Shionogi, personal fees from Shire, personal fees from Jannsen, personal fees from Celgene, outside the submitted work; M.T. reports personal fees from Bristol-Myers Squib, personal fees from Pfizer, outside the submitted work; K.M reports grants from Kyowa Hakko Kirin Co.
    [Show full text]
  • 1332 Nippon Suisan Kaisha, Ltd. 50 1333 Maruha Nichiro Corp. 500 1605 Inpex Corp
    Nikkei Stock Average - Par Value (Update:August/1, 2017) Code Company Name Par Value(Yen) 1332 Nippon Suisan Kaisha, Ltd. 50 1333 Maruha Nichiro Corp. 500 1605 Inpex Corp. 125 1721 Comsys Holdings Corp. 50 1801 Taisei Corp. 50 1802 Obayashi Corp. 50 1803 Shimizu Corp. 50 1808 Haseko Corp. 250 1812 Kajima Corp. 50 1925 Daiwa House Industry Co., Ltd. 50 1928 Sekisui House, Ltd. 50 1963 JGC Corp. 50 2002 Nisshin Seifun Group Inc. 50 2269 Meiji Holdings Co., Ltd. 250 2282 Nh Foods Ltd. 50 2432 DeNA Co., Ltd. 500/3 2501 Sapporo Holdings Ltd. 250 2502 Asahi Group Holdings, Ltd. 50 2503 Kirin Holdings Co., Ltd. 50 2531 Takara Holdings Inc. 50 2768 Sojitz Corp. 500 2801 Kikkoman Corp. 50 2802 Ajinomoto Co., Inc. 50 2871 Nichirei Corp. 100 2914 Japan Tobacco Inc. 50 3086 J.Front Retailing Co., Ltd. 100 3099 Isetan Mitsukoshi Holdings Ltd. 50 3101 Toyobo Co., Ltd. 50 3103 Unitika Ltd. 50 3105 Nisshinbo Holdings Inc. 50 3289 Tokyu Fudosan Holdings Corp. 50 3382 Seven & i Holdings Co., Ltd. 50 3401 Teijin Ltd. 250 3402 Toray Industries, Inc. 50 3405 Kuraray Co., Ltd. 50 3407 Asahi Kasei Corp. 50 3436 SUMCO Corp. 500 3861 Oji Holdings Corp. 50 3863 Nippon Paper Industries Co., Ltd. 500 3865 Hokuetsu Kishu Paper Co., Ltd. 50 4004 Showa Denko K.K. 500 4005 Sumitomo Chemical Co., Ltd. 50 4021 Nissan Chemical Industries, Ltd. 50 4042 Tosoh Corp. 50 4043 Tokuyama Corp. 50 WF-101-E-20170803 Copyright © Nikkei Inc. All rights reserved. 1/5 Nikkei Stock Average - Par Value (Update:August/1, 2017) Code Company Name Par Value(Yen) 4061 Denka Co., Ltd.
    [Show full text]
  • OCTOBER 2020 PTAB Public Hearing Schedule
    OCTOBER 2020 PTAB Public Hearing Schedule Proceeding No. Serial No. PARTY Date Time 2020-004197 16043641 BIOGEN MA INC Thursday, October 1, 2020 9:00 AM (EDT) ALLERGAN PHARMACEUTICALS 2020-002635 13907447 Thursday, October 1, 2020 9:00 AM (EDT) INTERNATIONAL LIMITED 2020-002276 13612925 BAYER AG (MONSANTO) Thursday, October 1, 2020 9:00 AM (EDT) 2020-002277 13612929 OTSUKA PHARMACEUTICAL CO., 2020-002304 14341306 Thursday, October 1, 2020 9:00 AM (EDT) LTD. 2020-002327 15893354 CELLECTIS Thursday, October 1, 2020 9:00 AM (EDT) 2020-000258 15163285 POLY GROUP LLC Thursday, October 1, 2020 9:00 AM (PDT) 2020-000640 15414456 DISCERNDX INC. Thursday, October 1, 2020 9:00 AM (PDT) 2020-000934 13982470 DENOVO BIOMARKERS INC. Thursday, October 1, 2020 9:00 AM (PDT) THE BOARD OF TRUSTEES OF THE 2020-001247 15175848 LELAND STANFORD JUNIOR Thursday, October 1, 2020 9:00 AM (PDT) UNIVERSITY EDWARDS LIFESCIENCES 2020-001487 14563866 Thursday, October 1, 2020 9:00 AM (PDT) CORPORATION IKEDA FOOD RESEARCH COL LTD 2020-003630 16145178 Thursday, October 1, 2020 1:00 PM (EDT) and PHC CORPORATION 2020-002049 13310632 ADARE PHARMACEUTICALS INC. Thursday, October 1, 2020 1:00 PM (EDT) 2020-000053 13135898 OLEG ILLICH EPSHTEIN Thursday, October 1, 2020 1:00 PM (EDT) 2020-001829 15008646 MERZ PHARMA GMBH & CO. KGAA Thursday, October 1, 2020 1:00 PM (EDT) 2020-002360 15407037 IONIS PHARMACEUTICALS INC. Thursday, October 1, 2020 1:00 PM (EDT) 2020-002113 13729631 L'OREAL Thursday, October 1, 2020 1:00 PM (EDT) 2019-003658 13576565 QUNZHU LI and LI LI Thursday, October 1, 2020 1:00 PM (EDT) 2020-000322 14136660 CYTEC INDUSTRIES INC.
    [Show full text]
  • View a Copy of This Licence, Visit Tivecommons.Org/Licenses/By/4.0
    Katakami et al. Cardiovasc Diabetol (2020) 19:110 https://doi.org/10.1186/s12933-020-01079-4 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Tofoglifozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study Naoto Katakami1,2* , Tomoya Mita3, Hidenori Yoshii4, Toshihiko Shiraiwa5, Tetsuyuki Yasuda6, Yosuke Okada7, Keiichi Torimoto7, Yutaka Umayahara8, Hideaki Kaneto9, Takeshi Osonoi10, Tsunehiko Yamamoto11, Nobuichi Kuribayashi12, Kazuhisa Maeda13, Hiroki Yokoyama14, Keisuke Kosugi15, Kentaro Ohtoshi16, Isao Hayashi17, Satoru Sumitani18, Mamiko Tsugawa19, Kayoko Ryomoto20, Hideki Taki21, Tadashi Nakamura22, Satoshi Kawashima23, Yasunori Sato24, Hirotaka Watada3 and Iichiro Shimomura1 on behalf of the UTOPIA study investigators Abstract Background: This study aimed to investigate the preventive efects of tofoglifozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disease (CVD) by monitoring carotid intima-media thickness (IMT). Methods: This prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study included 340 subjects with T2DM and no history of apparent CVD recruited at 24 clinical units. Subjects were randomly allocated to either the tofoglifozin treatment group (n 169) or conventional treatment group using drugs other than SGLT2 inhibitors (n 171). Primary outcomes were changes= in mean and maximum common carotid IMT measured by echography during= a 104-week treatment period. Results: In a mixed-efects model for repeated measures, the mean IMT of the common carotid artery (mean- IMT-CCA), along with the right and left maximum IMT of the CCA (max-IMT-CCA), signifcantly declined in both the tofoglifozin ( 0.132 mm, SE 0.007; 0.163 mm, SE 0.013; 0.170 mm, SE 0.020, respectively) and the control group ( 0.140 mm,− SE 0.006; 0.190 mm,− SE 0.012; 0.190 mm,− SE 0.020, respectively).
    [Show full text]
  • OSB Participant List by Research Area
    OSB Participant List by Research Area Contact Centers (CC) • AARP • Air Products and • American Drug Stores Chemicals • AAA • ABB • American Electric Power • Airbus • Accor • Abbott • American Express • Alcatel Lucent • American Electric Power • Abengoa • American International • Alcoa Group • American International • Abu Dhabi National Group Energy Company • Alcon • American Stores Company • Austin Energy • ACC Limited • Alfa • American Water • Bank of America • Access Insurance Holdings • Algonquin Power & • Amgen Utilities • Blue Cross Blue Shield • Accord Holdings • AMIL • ALH Group • Charles Schwab & • ACE • AmInvestment Bank Company • Alitalia • Acea • AMR • Citigroup • ALK Abello • Acer • Amssi • Citizens Gas • Alkermes • Acxiom • Amtran Logistics • Clarke American • Allergan • Adelaide Clinic Holdings • Andrew Corporation • CPS Energy • Alliance & Leicester • Adidas • Anglian Water Services • Direct Energy • Alliance Boots • Advance Food Company • Anritsu • Federal Reserve Bank of • Alliant Techsystems Minneapolis • Advance Publications • Anschutz • Allianz • John Deere • Advanced Coating • Apache • Allied Irish Banks • Technologies Louisville Water Company • Apex Equity Holdings • Advanced Semiconductor • Allstate Insurance • Manila Electric Company Engineering Company • Apple • • • Mellon Financial Adventist Health System Ally Financial • Arcadia Housing • • • MetLife Aegon Alon USA Energy • Arcos Dorados Holdings • • • Morgan Stanley AEON AlpTransit Gotthard • Ardent Health Services • • • NetBank Aera Energy Alstom • Argos •
    [Show full text]
  • ANNUAL REPORT 2016 Corporate Philosophy
    ANNUAL Otsuka Holdings Co., Ltd. ANNUAL REPORT 2016 REPORT 2016 For the year ended December 31, 2016 Corporate Philosophy Creating innovative products These words embody our commitment to: Contributing Improving to the human health lives of people worldwide In keeping with this corporate philosophy and the Otsuka mottos of Jissho (Actualization) and Sozosei (Creativity), the Otsuka Group strives to utilize its unique resources and skills to develop differentiated scientific solutions which contribute to the lives of people worldwide in the form of innovative and creative products ranging from pharmaceuticals to consumer products. We are striving to cultivate a culture and a dynamic corporate climate reflecting our vision as a healthcare company. Consistent with this approach, we are dedicated to achieving global sustainability, to our relationships with local communities, and to the protection of the natural environment. Contents About Otsuka Creating Corporate Value Corporate Philosophy Corporate Governance ............. 42 Directors, Audit & Supervisory Business Model ......................... 02 Board Members ........................ 48 Corporate Social Business Segments ................... 04 Responsibility ........................... 50 Financial and Non-Financial Finance & General Information Highlights ................................. 06 Financial Summary ................... 54 Consolidated Financial Statements ................ 56 Message from the President ..... 08 Group Structure & Overview of Main Operating Companies .....
    [Show full text]
  • FTSE Japan ESG Low Carbon Select
    2 FTSE Russell Publications 19 August 2021 FTSE Japan ESG Low Carbon Select Indicative Index Weight Data as at Closing on 30 June 2021 Constituent Index weight (%) Country Constituent Index weight (%) Country Constituent Index weight (%) Country ABC-Mart 0.01 JAPAN Ebara 0.17 JAPAN JFE Holdings 0.04 JAPAN Acom 0.02 JAPAN Eisai 1.03 JAPAN JGC Corp 0.02 JAPAN Activia Properties 0.01 JAPAN Eneos Holdings 0.05 JAPAN JSR Corp 0.11 JAPAN Advance Residence Investment 0.01 JAPAN Ezaki Glico 0.01 JAPAN JTEKT 0.07 JAPAN Advantest Corp 0.53 JAPAN Fancl Corp 0.03 JAPAN Justsystems 0.01 JAPAN Aeon 0.61 JAPAN Fanuc 0.87 JAPAN Kagome 0.02 JAPAN AEON Financial Service 0.01 JAPAN Fast Retailing 3.13 JAPAN Kajima Corp 0.1 JAPAN Aeon Mall 0.01 JAPAN FP Corporation 0.04 JAPAN Kakaku.com Inc. 0.05 JAPAN AGC 0.06 JAPAN Fuji Electric 0.18 JAPAN Kaken Pharmaceutical 0.01 JAPAN Aica Kogyo 0.07 JAPAN Fuji Oil Holdings 0.01 JAPAN Kamigumi 0.01 JAPAN Ain Pharmaciez <0.005 JAPAN FUJIFILM Holdings 1.05 JAPAN Kaneka Corp 0.01 JAPAN Air Water 0.01 JAPAN Fujitsu 2.04 JAPAN Kansai Paint 0.05 JAPAN Aisin Seiki Co 0.31 JAPAN Fujitsu General 0.01 JAPAN Kao 1.38 JAPAN Ajinomoto Co 0.27 JAPAN Fukuoka Financial Group 0.01 JAPAN KDDI Corp 2.22 JAPAN Alfresa Holdings 0.01 JAPAN Fukuyama Transporting 0.01 JAPAN Keihan Holdings 0.02 JAPAN Alps Alpine 0.04 JAPAN Furukawa Electric 0.03 JAPAN Keikyu Corporation 0.02 JAPAN Amada 0.01 JAPAN Fuyo General Lease 0.08 JAPAN Keio Corp 0.04 JAPAN Amano Corp 0.01 JAPAN GLP J-REIT 0.02 JAPAN Keisei Electric Railway 0.03 JAPAN ANA Holdings 0.02 JAPAN GMO Internet 0.01 JAPAN Kenedix Office Investment Corporation 0.01 JAPAN Anritsu 0.15 JAPAN GMO Payment Gateway 0.01 JAPAN KEWPIE Corporation 0.03 JAPAN Aozora Bank 0.02 JAPAN Goldwin 0.01 JAPAN Keyence Corp 0.42 JAPAN As One 0.01 JAPAN GS Yuasa Corp 0.03 JAPAN Kikkoman 0.25 JAPAN Asahi Group Holdings 0.5 JAPAN GungHo Online Entertainment 0.01 JAPAN Kinden <0.005 JAPAN Asahi Intecc 0.01 JAPAN Gunma Bank 0.01 JAPAN Kintetsu 0.03 JAPAN Asahi Kasei Corporation 0.26 JAPAN H.U.
    [Show full text]
  • Daiichi Sankyo Company, Limited
    [Translation] CONVOCATION NOTICE OF THE 14TH ORDINARY GENERAL MEETING OF SHAREHOLDERS For the Fiscal Year Ended March 31, 2019 Daiichi Sankyo Company, Limited *Note: This translation does not include pictures, charts etc. originally issued in the Japanese version. - 1 - [Translation] To Our Shareholders At the Daiichi Sankyo Group (“the Group”), we are proceeding with the initiatives of 4th mid- term business plan with the aim of becoming a “Global Pharma Innovator with Competitive Advantage in Oncology” as set forth in our 2025 Vision. In fiscal 2018, we made significant progress in developing new drugs in oncology area, including DS-8201, an antibody drug conjugates utilizing our proprietary technologies. In addition, we entered into a strategic collaboration agreement with AstraZeneca, which has strengths in the oncology business, for the global development and commercialization of DS-8201 in order to maximize its value. Furthermore, sales of mainstay products such as edoxaban, an anticoagulant which supports current earnings of the Group, were firm in Japan and overseas. The achievement of initial target of mid-term business plan for fiscal 2020 is expected to be delayed by two years due to failure of achievement of the plan for pain franchise business and additional investments in research and development. However, we are gaining confidence of achieving our 2025 Vision and accelerating growth in the future due to the significant improvement in the value of oncology area pipelines. We will continue to make every effort to achieve the goals of the Medium-Term Management Plan and 2025 Vision. I greatly appreciate your continued support in the future.
    [Show full text]
  • Daiichi Sankyo Group Value Report 2019
    External Evaluations (as of June 30,2019) ™ Daiichi Sankyo Group Value Report 2019 Value Daiichi Sankyo Group MSCI Japan Empowering Women Select Index THE INCLUSION OF DAIICHI SANKYO CO.,LTD. IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF DAIICHI SANKYO CO.,LTD. BY MSCI OR ANY OF ITS AFFILIATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADE- MARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES. “Eruboshi” Certification Mark “Kurumin” Certification Mark Logo given to Certified Health and Productivity Management Organization (White500) This report uses FSC® certified paper, which indicates that the paper used to print this Paper report was produced from properly managed forests. 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan This report was printed using 100% Inks biodegradable printing inks from vegetable Corporate Communications Department oil. Daiichi Sankyo Group Tel: +81-3-6225-1126 CSR Department The waterless printing method used for this Value Report 2019 Tel: +81-3-6225-1067 Printing report minimized the use and release of harmful liquid wastes. https://www.daiichisankyo.com/ Printed in Japan 005_7045687911909.indd 1 2019/09/27 18:22:19 Introduction Our Mission The Core Values and Commitments serve as the criteria for business activities and In addition, we have established the DAIICHI SANKYO Group Corporate Conduct Charter . decision-making used by executive officers and employees in working to fulfill Our Mission . This charter calls on us to fulfill our social responsibilities by acting with the highest ethical Our Corporate Slogan succinctly explains the spirit of Our Mission, Core Values and standards and a good social conscience appropriate for a company engaged in business Commitments.
    [Show full text]
  • Convocation Notice of the 16Th Ordinary General Meeting of Shareholders
    [Translation] CONVOCATION NOTICE OF THE 16TH ORDINARY GENERAL MEETING OF SHAREHOLDERS For the Fiscal Year Ended March 31, 2021 Daiichi Sankyo Company, Limited *Note: This translation does not include pictures, charts etc. originally issued in the Japanese version. [Translation] To Our Shareholders We sincerely appreciate the continuous kindness of our shareholders. In addition, we would like to express our deepest sympathies to those who passed away due to COVID-19, and thank the medical personnel who are close to those who are fighting illness and are making efforts in treatment. We will continue to devote ourselves to the research and development of vaccines and therapeutic agents. Our “Purpose” is to “contribute to the enrichment of quality of life around the world.” As a pharmaceutical company with strengths in science and technology, we continuously create innovative pharmaceuticals and provide pharmaceuticals that meet diverse medical needs to provide sustainable value to society. We were able to launch the anti-cancer drug “Enhertu”, which is an antibody-drug conjugate (ADC) that utilizes our unique technology, in Japan and Europe in fiscal 2020, following the launch in the U.S. in fiscal 2019. Subsequent ADCs such as Dato-DXd and HER3-DXd are also steadily developing. Now, we have newly established our 2030 Vision of being an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society,” and have established 5-Year Business Plan (fiscal 2021 to fiscal 2025) as a plan to realize our 2025 Vision, “Global Pharma Innovator with Competitive Advantage in Oncology.” By working together as a Daiichi Sankyo Group on 5-Year Business Plan toward the 2030 Vision, we aim to solve the social issues expected of our company and increase shareholder value.
    [Show full text]
  • Daiichi Sankyo Company, Limited
    [Translation] CONVOCATION NOTICE OF THE 6TH ORDINARY GENERAL MEETING OF SHAREHOLDERS For the Fiscal Period Ended March 31, 2011 Daiichi Sankyo Company, Limited - 1 - [Translation] (Securities Identification Code 4568) May 31, 2011 To Shareholders, Daiichi Sankyo Company, Limited Joji Nakayama, Representative Director and President & CEO 5-1, Nihonbashi Honcho 3-chome, Chuo-ku, Tokyo, Japan CONVOCATION NOTICE OF THE 6TH ORDINARY GENERAL MEETING OF SHAREHOLDERS We wish to extend our deepest sympathy to all those who have suffered hardship from the Great East Japan Earthquake that occurred in March 2011. Daiichi Sankyo Company, Limited (“the Company”) respectfully requests your attendance at the 6th Ordinary General Meeting of Shareholders (“the Meeting”), which will be held as detailed below. If you will not be able to attend the Meeting, you may exercise your voting rights through either of the methods described below, in which case we ask that you please exercise your voting rights by 17:30 (within our business hours), Friday, June 24, 2011 (Japan Time), after examining the attached reference documents. [Exercise of Voting Rights by Mail] Please indicate your approval or disapproval for the proposals on the enclosed voting form and return the form to the Company. Please note that the form must be received by the Company no later than the above-mentioned deadline. [Exercise of Voting Rights on the Internet etc.] After examining “Information on Exercise of Voting Rights, etc.” on pages 57 and 58, please vote on the Internet at the dedicated voting website (http://www.evote.jp/) no later than the above-mentioned deadline. The Company is participating in the platform for electronic exercise of voting rights for institutional investors operated by ICJ Inc.
    [Show full text]
  • 【Research Report】The GR Scores 2018
    Nikko Research Review Research Report Aug. 2019 The GR Scores 2018 Institute of Social System Research Megumi Terayama Yasuyuki Sugiura Abstract Nikko Research Center, Inc. has developed the Governance Research Scores (GR scores), which evaluate the strength of corporate governance in Japanese companies. We list the GR Scores of 100 Is major domestic companies by benchmarking their practices against Japan’s Corporate Governance Code as the domestic standard, and the ICGN Global Governance Principles as the global standard. Here, we report the GR Scores 2018 as of December 31, 2017 in sequential form. The overall domestic average score rose 3.1 points to 51.6% from the previous year. Sixty-nine companies had higher domestic scores, and only eight companies had lower scores, compared with the previous year. Disclosing the result of board evaluations, conducting effective board meetings, and setting targets such as earnings in the medium-term management plan seemed to drive this improvement in scores. The overall global average score also rose 1.4 points to 22.3% from the previous year; however, it remains low. While 63 companies had higher global scores, 25 companies had lower scores compared with the previous year. The main reasons for the rise include easing of the requirement of independence for controlled companies by ICGN in their revised principles and a certain number of companies adopting restricted stock for management compensation. By contrast, a tightening of the independence requirement for the audit committee lowered the global scores. Table of Contents 1. Introduction 2. Outline of the GR Scores 2018 2.1 Evaluation method 2.2 Revision of evaluation items from the GR Scores 2017 3.
    [Show full text]